

Wojciech Jurczak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3165702/publications.pdf>

Version: 2024-02-01

137
papers

10,247
citations

109321

35
h-index

36028

97
g-index

140
all docs

140
docs citations

140
times ranked

8432
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97.	0.4	6
2	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. <i>Blood Advances</i> , 2022, 6, 1296-1308.	5.2	42
3	Static and Dynamic Properties of Al-Mg Alloys Subjected to Hydrostatic Extrusion. <i>Materials</i> , 2022, 15, 1066.	2.9	2
4	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 351-363.	27.0	278
5	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
6	The Analysis of the Strength of the Ship's Hull After Running Aground. , 2022, 224, 16-27.		0
7	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	3.7	13
8	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1066-1076.	1.3	3
9	Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 455-463.	3.1	24
10	Submarine Resistance Force Characteristics Determination after Modification of Depth Rudder System. <i>Advances in Science and Technology Research Journal</i> , 2021, 15, 1-9.	0.8	0
11	Influence of Hydrostatic Extrusion on the Mechanical Properties of the Model Al-Mg Alloys. <i>Journal of Materials Engineering and Performance</i> , 2021, 30, 3502-3509.	2.5	3
12	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021, 397, 892-901.	13.7	260
13	Surface Finish Analysis in Single Point Incremental Sheet Forming of Rib-Stiffened 2024-T3 and 7075-T6 Alclad Aluminium Alloy Panels. <i>Materials</i> , 2021, 14, 1640.	2.9	16
14	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	1.6	132
15	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
16	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	7.2	25
17	Umbralisib, a Dual PI3K/CK1 μ Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1609-1618.	1.6	111
18	Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. <i>Advances in Therapy</i> , 2021, 38, 3113-3128.	2.9	8

#	ARTICLE	IF	CITATIONS
19	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
20	Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2417-2426.	3.5	81
21	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. <i>Leukemia and Lymphoma</i> , 2021, 62, 3440-3451.	1.3	6
22	Integrated safety analysis of umbralisib, a dual PI3K \hat{I} /CK1 $\hat{\mu}$ inhibitor, in relapsed/refractory lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 5332-5343.	5.2	13
23	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	5.2	6
24	Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 179.	17.0	33
25	EFFECT OF HUMIDITY ON TRIBOLOGICAL PROPERTIES OF SELECTED FRICTION JUNCTIONS WITH AN EVALUATION OF ACOUSTIC EMISSION. <i>Tribologia</i> , 2021, 297, 9-18.	0.2	1
26	Outcomes of treatment with dose-adjusted EPOCH or R \hat{C} HOP in primary mediastinal large B \hat{C} ell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 59-66.	2.2	25
27	First \hat{C} line R \hat{C} V \hat{P} versus R \hat{C} HOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. <i>British Journal of Haematology</i> , 2020, 188, 898-906.	2.5	16
28	Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00649.	2.4	2
29	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
30	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	1.1	8
31	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <i>Advances in Medical Sciences</i> , 2020, 65, 371-377.	2.1	2
32	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr \hat{A} m macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	1.4	281
33	Phase 1/2a study of ^{177}Lu -lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	5.2	33
34	The Rapeseed Oil Based Organofunctional Silane for Stainless Steel Protective Coatings. <i>Materials</i> , 2020, 13, 2212.	2.9	5
35	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 2849-2861.	1.6	235
36	Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 978-988.	10.7	320

#	ARTICLE	IF	CITATIONS
37	Cardio-oncology for better lymphoma therapy outcomes. <i>Lancet Haematology</i> , 2020, 7, e273-e275.	4.6	1
38	Rituximab biosimilars in clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 1523-1524.	1.3	1
39	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report. <i>Scientific Reports</i> , 2020, 10, 3517.	3.3	12
40	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. <i>Annals of Hematology</i> , 2020, 99, 1073-1079.	1.8	5
41	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , 2020, 395, 1278-1291.	13.7	393
42	Prediction of Welding-Induced Distortion of Fixed Plate Edge Using Design of Experiment Approach. <i>Polish Maritime Research</i> , 2020, 27, 134-142.	1.9	7
43	Mechanical Properties of Welded Joints of 1.3964 Steel for Computer Aided Engineering (CAE) Purposes. <i>Scientific Journal of Polish Naval Academy</i> , 2020, 220-221, 15-28.	0.2	0
44	Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group*. <i>Leukemia and Lymphoma</i> , 2019, 60, 341-348.	1.3	6
45	Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. <i>Future Oncology</i> , 2019, 15, 4223-4234.	2.4	8
46	The influence of Mg addition and hydrostatic extrusion HE on the repassivation ability of pure Al, AlMg1 and AlMg3 model alloys in 3.5 wt-% NaCl. <i>Corrosion Engineering Science and Technology</i> , 2019, 54, 666-672.	1.4	2
47	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1045-1056.	3.1	13
48	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	1.3	16
49	Consolidation with ⁹⁰ Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	1.3	6
50	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
51	The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. <i>Cancer Medicine</i> , 2019, 8, 1103-1109.	2.8	15
52	Avatrombopag for the treatment of immune thrombocytopenia. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 327-339.	3.0	12
53	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma – Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	3.3	3
54	Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 173.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Treatment of high-risk follicular lymphoma. <i>HemaSphere</i> , 2019, 3, 85-87.	2.7	0
56	Helping the cardio-oncologist: from real life to guidelines. <i>Seminars in Oncology</i> , 2019, 46, 433-436.	2.2	1
57	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019, 6, e67-e78.	4.6	146
58	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	3.1	9
59	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
60	The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. <i>Future Oncology</i> , 2019, 15, 305-317.	2.4	5
61	ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 31-31.	1.4	47
62	The necessity of post-induction therapy in mantle cell lymphoma patients: A multicenter retrospective real-world analysis by Polish Lymphoma Research Group (PLRG). <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2019, 73, 303-309.	0.1	1
63	Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 259-266.	0.4	0
64	Stosowanie lek w biopodobnych w hematologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów. <i>Acta Haematologica Polonica</i> , 2019, 50, 51-56.	0.3	0
65	Chłoniak z komórek płaszczka – rola terapii celowanych. <i>Acta Haematologica Polonica</i> , 2019, 50, 116-120.	0.3	0
66	Passive Corrosion Protection of Al-Zn-Mg alloy in Seawater. <i>Nase More</i> , 2019, 66, 103-111.	0.5	0
67	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	27.0	564
68	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2018, 391, 659-667.	13.7	324
69	Prospective subgroup analyses of the randomized MCL (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 224-235.	2.5	10
70	Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 670-678.	1.3	8
71	Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2405-2412.	1.6	81
72	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257

#	ARTICLE	IF	CITATIONS
73	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> ,the, 2018, 5, e543-e553.	4.6	53
74	Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. <i>Chemotherapy</i> , 2018, 63, 238-245.	1.6	17
75	Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 183, 479-490.	2.5	131
76	Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. <i>British Journal of Haematology</i> , 2018, 183, 400-410.	2.5	18
77	Microstructure, Mechanical Properties, and Corrosion Resistance of Thermomechanically Processed AlZn6Mg0.8Zr Alloy. <i>Materials</i> , 2018, 11, 570.	2.9	6
78	Microstructural and Fractographic Analysis of Plastically Deformed Al-Zn-Mg Alloy Subjected to Combined High-Cycle Bending-Torsion Fatigue. <i>Metals</i> , 2018, 8, 487.	2.3	6
79	Use of acalabrutinib in patients with mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2018, 11, 495-502.	2.2	9
80	Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 421-426.	0.4	8
81	Corrosion Influence on Safety of Hydraulic Pipelines Installed on Decks of Contemporary Product and Chemical Tankers. <i>Polish Maritime Research</i> , 2018, 25, 71-77.	1.9	6
82	Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience. <i>Acta Haematologica Polonica</i> , 2018, 49, 228-233.	0.3	1
83	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	10.7	219
84	Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. <i>International Journal of Cardiology</i> , 2017, 235, 147-153.	1.7	8
85	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus tamsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	1.3	15
86	Research on Biosimilars: pivotal trials and principles. <i>Lancet Haematology</i> ,the, 2017, 4, e409-e410.	4.6	1
87	Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. <i>Lancet Haematology</i> ,the, 2017, 4, e350-e361.	4.6	69
88	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> ,the, 2017, 4, e362-e373.	4.6	70
89	Rytuksymab – pierwsze biopodobne przeciwciało, a monoklonalne w hematoonkologii. <i>Acta Haematologica Polonica</i> , 2017, 48, 269-273.	0.3	1
90	Is Good Clinical Practice Becoming Poor Clinical Care?. <i>HemaSphere</i> , 2017, 1, e4.	2.7	3

#	ARTICLE	IF	CITATIONS
91	Corrosion of ammunition dumped in the Baltic Sea. Journal of KONBiN, 2017, 41, 227-246.	0.4	16
92	Possibilities of Belzona Adhesive Joints Application for Austenitic Steel Used in Ship Constructions. Advances in Science and Technology Research Journal, 2017, 11, 134-140.	0.8	0
93	Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy. Wspolczesna Onkologia, 2016, 4, 297-301.	1.4	2
94	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations. Oncotarget, 2016, 7, 38180-38190.	1.8	130
95	Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma. American Journal of Therapeutics, 2016, 23, e749-e756.	0.9	9
96	Influence of Friction Stir Welding (FSW) on Mechanical and Corrosion Properties of AW-7020M and AW-7020 Alloys. Polish Maritime Research, 2016, 23, 86-90.	1.9	3
97	Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report. Journal of Medical Case Reports, 2016, 10, 123.	0.8	8
98	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2016, 17, 768-778.	10.7	676
99	Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 2016, 127, 1559-1563.	1.4	228
100	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, The, 2016, 387, 770-778.	13.7	389
101	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002); Tj ETQq1 1 0.784314 rgBT /Overlo 10.7 135	10.7	135
102	Design Methodology of Strength Verification of Platform During Load Out of the Arkutun Dagi SE-Topside 43.800 MT. Polish Maritime Research, 2016, 23, 117-128.	1.9	4
103	Study of the Corrosion Resistance of Ship Aluminium Alloys. Scientific Journal of Polish Naval Academy, 2016, 206, 37-65.	0.2	6
104	Impact Resistance of Aluminium Ship Structures. Scientific Journal of Polish Naval Academy, 2016, 207, 45-54.	0.2	0
105	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 2015, 126, 739-745.	1.4	349
106	Impact and Ballistic Resistance of a New Aluminium Alloy for Ship Construction Elements. Polish Maritime Research, 2015, 22, 72-78.	1.9	4
107	The use of Yttrium-90 Ibritumomab Tiuxetan (90 Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation. Wspolczesna Onkologia, 2015, 1, 43-47.	1.4	2
108	Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study. Wspolczesna Onkologia, 2015, 3, 214-219.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	1.6	394
110	Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers. <i>Medical Oncology</i> , 2015, 32, 90.	2.5	8
111	Gemcitabine-Based Treatment in Poor Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma – a Multicenter Polish Experience. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 783-789.	1.4	5
112	MICROSCOPIC EXAMINATION OF AlZn5Mg1 ALLOY JOINTS WELDED BY FSW AND MIG. <i>Journal of KONES</i> , 2015, 19, 129-135.	0.2	1
113	Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 741-748.	0.4	5
114	The Exploitation Problems Marine Light Constructions for Corrosion Resistance / Problemy Eksploatacyjne Lekkich Konstrukcji Morskich w Aspekcie Odporności Korozyjnej. <i>Journal of KONBIN</i> , 2015, 33, 5-18.	0.4	0
115	Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 325.	0.8	2
116	Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 791-799.	2.3	53
117	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
118	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chłoniakiem z komórkami B – wyniki międzynarodowego, wielośrodkowego, badania II fazy z ibrutinibem (PCI-32765) – EHA.3 Encore. <i>Acta Haematologica Polonica</i> , 2013, 44, 314-318.		1
119	Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – A national multicenter study. <i>International Journal of Cardiology</i> , 2013, 168, 5212-5217.	1.7	41
120	Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 589-595.	0.4	6
121	Dynamic properties of 7000 - series aluminum alloys at large strain rates. <i>Polish Maritime Research</i> , 2012, 19, .	1.9	5
122	Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results. <i>Medical Oncology</i> , 2012, 29, 2070-2076.	2.5	0
123	A Twelve-Year Follow-Up Study on a Case of Early-Onset Parkinsonism Preceding Clinical Manifestation of Gaucher Disease. <i>JIMD Reports</i> , 2011, 3, 53-57.	1.5	4
124	Modelling of the Ship Structural Ballistic Shields from the 10GHMBA Steel. <i>Solid State Phenomena</i> , 2011, 180, 303-312.	0.3	2
125	Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. <i>Leukemia and Lymphoma</i> , 2010, 51, 1612-1622.	1.3	21
126	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. <i>European Journal of Cancer</i> , 2008, 44, 366-373.	2.8	25

#	ARTICLE	IF	CITATIONS
127	The effect of heat treatment on the structure and corrosion resistance of Al-Zn-Mg alloys. Polish Maritime Research, 2008, 15, 66-71.	1.9	4
128	Comparative Electrochemical Analysis of the Passive Layer Cracking Process on Aluminum Alloys Performed by Means of DC and AC Techniques. Journal of the Electrochemical Society, 2007, 154, C74.	2.9	20
129	Quadratic Cohen representations in spectral analysis of serration process in Al-Mg alloys. Computational Materials Science, 2007, 39, 880-886.	3.0	14
130	The effect of tensile stresses on aluminium passive layer durability. Electrochimica Acta, 2006, 51, 6091-6096.	5.2	21
131	The effect of strain rate on the passive layer cracking of 304L stainless steel in chloride solutions based on the differential analysis of electrochemical parameters obtained by means of DEIS. Journal of Electroanalytical Chemistry, 2005, 576, 277-285.	3.8	20
132	Passive Layer Cracking Studies Performed on A95056 Aluminum Alloy by DEIS and Acoustic Emission. Electrochemical and Solid-State Letters, 2005, 8, B55.	2.2	17
133	Damage and Corrosion Diagnostics of Welded Light Alloys Ship Constructions. Solid State Phenomena, 0, 196, 20-27.	0.3	4
134	Simulating the Impact of Exposure to Corrosive Medium on Cracking Initiation in AW7020M Alloy Specimens. Solid State Phenomena, 0, 210, 130-135.	0.3	2
135	Exploitation Load Impact on Electrochemical Properties of Shipbuilding 7xxx Series Aluminum Alloy Joints Prepared with TIG and FSW Methods. Solid State Phenomena, 0, 236, 53-61.	0.3	0
136	Effect of Frictional-Mechanical Treatment of the Low Alloy Steels on Some Exploitation Properties in Sea Water Simulated Solution. Solid State Phenomena, 0, 250, 56-60.	0.3	3
137	Ocena profilu korzyści i ryzyka leczenia idelalizybem u chorych na przewlekłą... białaczkę™ limfocytową... i chłoniaki nie-Hodgkina. Hematologia, 0, , .	0.0	0